BBIO - Why did BridgeBio Pharma stock surge today? Data on achondroplasia asset
2023-03-06 18:08:08 ET
- BridgeBio Pharma ( NASDAQ: BBIO ) reached a 52-week high Monday of $19.39 and closed up 52% due to positive mid-stage results on achondroplasia candidate infigratinib.
- Data showed 80% of children at six months were responders.
- BridgeBio ( BBIO ) has already begun enrolling for a phase 3 trial of infigratinib .
- Seeking Alpha contributor Edmund Ingham, who rates BridgeBio ( BBIO ) a buy, provides an assessment of one of the company's phase 3 candidates, acoramidis for transthyretin amyloidosis (ATTR) .
For further details see:
Why did BridgeBio Pharma stock surge today? Data on achondroplasia asset